The availability of acellular pertussis vaccines, which appear to be both safe and immunogenic in adults, will require that vaccine advisory groups make recommendations regarding their use. Pertussis in adults has negligible mortality but is responsible for about one-quarter of cases of chronic cough syndrome in young adults. Parents and other infant caregivers are important transmitters of pertussis to infants, the group who have the highest morbidity and mortality. Assuming that further studies confirm the immunogenicity and safety profile of acellular pertussis vaccines in adults, recommendations can be made for its use for universal immunization of adolescents, epidemic control, and strongly considered targeted adults who give care to infants. Factors that mitigate against including acellular pertussis vaccine in the recommended decennial tetanus-diphtheria toxoids booster include the short duration of the immune response to the acellular pertussis vaccine, increased cost and reactogenicity, and the lack of vaccine delivery systems to most adults. The elderly and the infirm, who are the current focus of adult immunization programs, are unlikely candidates for pertussis immunization. Therefore, recommendations for use of acellular pertussis vaccine in adults should be selective, rather than universal.
The changes sweeping the health care system in the United recipient from mortality and/or morbidity. In addition, many vaccines have a societal benefit in reducing transmission to States favor preventive measures, including immunization. The Childhood Immunization Initiative has resulted in record imothers, particularly those at high risk. Cost-benefit studies have demonstrated, for most of the universally recommended vacmunization levels among U.S. children. Polio has been eradicated from the Western Hemisphere, and õ100 children die cines, significant savings both to the individual and to society, especially if the indirect costs are included. In some instances annually from vaccine-preventable diseases. Unfortunately, adult immunizations receive much less attention, although (smallpox and soon polio), widespread immunization can lead to eradication of the disease. ú99% of deaths from vaccine-preventable disease occur in adults [1] . In the United States, an estimated 50,000 -70,000 persons die each year from pneumococcal infection, influenza, Determinants of Vaccine Priority and hepatitis B -related illness (table 1) . To put this in perspective, this is equivalent to the total U.S. death toll in the Vietnam
The priority given to use of a particular vaccine is the result War and exceeds the annual deaths from AIDS or automobile of many factors (table 3) . Chief among these is the importance accidents in the United States. Even the modest goals of achievof the disease, both to the individual and to society. The enthuing 60% immunization levels for pneumococcal and influenza siasm that greeted effective polio vaccines stands in contrast to vaccines among the elderly by the year 2000 can have an the tepid response in the United States to the recently developed important impact, and if adult levels were to reach the pediatric vaccines to prevent diarrhea due to rotaviruses. The effectivestandard (ú90% immunization rates), ú25,000 deaths per year ness of a vaccine in preventing or modifying the disease and could be prevented, despite the fact that the current vaccines reducing colonization and transmission, the duration of benefit, have only limited effectiveness. The proposal to immunize all and the safety profile are other major considerations influencing adults with acellular pertussis vaccine will need to be evaluated policy. Particularly for a disease of low mortality (e.g., pertussis in comparison with other adult vaccine priorities.
in adults), cost-benefit analyses are major determinants of recommendations for vaccine use. Feasibility issues are also important. For example, can the First Principles of Vaccine Policy vaccine be combined with other antigens in an already accepted The primary principles of vaccine policy are summarized in schedule, without additional vaccine-related morbidity? Do detable 2. The main benefit of an immunization is to protect the livery systems exist for getting the vaccine to the targeted populations? [1] .
• Access to targeted populations * From [1 -3] . † These composites from [1 -3] indicate efficacy in immunoncompetent adults. In the elderly and immunocompromised, efficacy estimates are lower.
‡ Percentage of targeted groups who are in compliance with current recommendations. These are overall composite rates from [2 -4] . Rates are variable with AIDS in the early 1980s, before the availability of serotestamong different targeted groups.
ing for HIV allowed a broader case definition and established § (Potential additional vaccine utilization) 1 (estimated vaccine efficacy) 1 more precise means of defining cases.
(estimated annual deaths).
x Variable (range, 0 -40,000).
Settings in which adult transmission of pertussis is clearly Ø Highly variable (1% -60%) among different target groups.
important include the infection of infants by parents and other ** Estimate based on seroprevalence data.
caregivers (because of the severity and mortality of infant pertussis, reduction of pertussis among infant caregivers deserves the highest priority when considering the use of acellular perwith Bordetella pertussis are difficult to ascertain, because of tussis vaccines in adults) and outbreaks in closed adult populathe lack of strict case definitions and standards for serodiagnotions (e.g., college students, nursing home residents). sis, as well as the low sensitivity of both culture and antigen
In the general population, the relative role of adults versus detection tests [4, 5] . Evaluation of close contacts by nasophachildren in transmission of pertussis is not well defined, but chilryngeal cultures or by PCR to identify B. pertussis have not dren appear to be more important in community outbreaks [6] . demonstrated high levels of infection or carriage, despite epidemiological evidence that pertussis is a highly communicable Clinical Significance of Pertussis in Adults disease. The established opinion that there is little or no spread of pertussis by asymptomatically infected persons is challenged Although mortality from pertussis is a significant issue in by serosurveys that turn up many ''infections'' without clinical infants, it is essentially nil in adults [8] (table 5) . Pertussis in disease, as well as by the observation that in one-third to oneadults is a nuisance disease whose morbidity has been measured half of cases, there is no recognized contact with a case of by the prolonged cough syndrome. This can occur at any age pertussis [6, 7] . Until more precise tools for case and carrier but has been best evaluated in young adults, among whom ascertainment become available, the epidemiology will be based on clinical case definitions, which almost certainly miss milder and atypical infections. This is analogous to the situation Table 4 . Epidemiological factors involved in pertussis in adults.
• Limitations of case ascertainment tussis to their infants but also to boost maternal antibodies that might benefit their infants during the early months of life.
Mortality: essentially nil
Earlier studies of maternal pertussis immunization with whole Morbidity cell pertussis vaccines were inconclusive regarding benefit
• Prolonged cough syndrome: can occur at any age but best evaluated in [10 -14] , but these bear repeat study with the acellular pertussis young adults; more information is needed regarding its impact (hospitalization, absenteeism) and cost vaccines. The reluctance to immunize pregnant women is wan- . The acellular pertussis accounts for about one-fourth of those with cough pertussis vaccines should be evaluated for safety and benefit lasting ú2 weeks [6] . There is a paucity of data regarding the in this population. impact of adult pertussis on hospitalization, absenteeism, and
The exposure of infants to adults is primarily to parents and costs (both medical and indirect). Other potential pertussis morother providers of infant care, predominantly young adults, bidity in adults (e.g., exacerbations in patients with chronic rather than to the elderly (the group targeted for influenza and obstructive pulmonary disease) has not been well evaluated.
pneumococcal vaccines). To reduce infant risk, it would seem prudent and more cost-effective to focus efforts of pertussis immunization on targeted young adult groups rather than to Goals of Pertussis Immunization of Adults attempt to immunize all adults. Unfortunately, the duration of The primary benefit of immunizing adults is to reduce their the antibody response to the acellular pertussis vaccines is short risk of transmitting pertussis to infants (table 6), for whom the (Ç1 -2 years), although it is hoped that protective efficacy will disease has significant morbidity and mortality, especially in the be of longer duration. However, it appears that repeated boostearly months of life before active immunization is complete [8] .
ers will be necessary to ensure maximal protection. The feasiAnother benefit of adult immunization (table 6) is to reduce bility of repeatedly immunizing young adults is a serious probthe individual's own risk of developing persistent cough synlem. An adolescent immunization visit is becoming a standard drome. In addition, reducing transmission to older children or of pediatric practice, but there are no well-developed delivery young adults (persons who should have been actively immusystems to give boosters to older adults. Because new parents nized per the standard pediatric schedule) will contribute to and their families are highly attuned to (and motivated to preherd immunity as part of the overall reduction in and eventually vent) environmental risks to newborns, obstetrics caregivers eradication of pertussis.
and infant caregivers are the most obvious candidates among which to promote immunization of providers of infant care.
Strategy Options to Prevent Infant Pertussis
Impediments to Recommending Universal Acellular Active immunization of infants, beginning at 2 months of Pertussis Immunizations for Adults age, remains the cornerstone of prevention of pertussis in infants. Unfortunately, the three-dose schedule (diphtheriaCurrent morbidity and mortality data do not support a univerpertussis-tetanus, with whole cell or acellular pertussis vaccine) sal stand-alone recommendation for acellular pertussis vaccine is not complete until age 6 months, leaving infants susceptible in adults. There is need for more detailed information regarding during their period of maximal risk for severe morbidity and age-specific incidence of disease in adults of all ages, together mortality [5, 8] . Boosters for older children in their second with an analysis of health care costs and epidemiological imyear of life and at age 4 -6 years are part of the standard pact. There is also an important feasibility problem in that pediatric schedule and are requirements for school entry in young adults, the most important group in terms of preventing most states. The immunogenicity and good safety profile of transmission to children, do not get routine preventive care, acellular pertussis vaccines in older children and adults has led to strong consideration of additional boosters beyond school entry to further reduce transmission [6, 9] . Pertussis immuniza- Table 6 . Goals of pertussis immunization of adults.
tion of adolescents has the dual advantages of boosting individual protection at a time when immunity from preschool pertusPrimary goal: reduce transmission to infants who bear the brunt of pertussis sis immunization has largely waned and enhancing immunity mortality and morbidity Secondary goals: of persons as they enter the decades in which they are likely
• Reduce morbidity in older children and young adults to become parents.
• Reduce morbidity in all adults Pregnant women deserve special consideration for pertussis with the notable exception of pregnant women. Therefore, to stand-alone vaccine (state and local health departments will have a central role). Acellular pertussis vaccine should be achieve universal immunization of adults with acellular pertussis vaccines, a major new delivery system would need to be strongly considered for targeted adults who give care to infants. The high annual rate of pertussis seroconversion among health implemented. This is unlikely, given the fact that adult pertussis has negligible mortality and does not command a high priority care workers [6] suggests that they may be candidates for regular boosters. among adult preventive medicine practices.
The initially attractive idea of combining acellular pertussis vaccine with the adult tetanus-diphtheria toxoids vaccine has What Do We Need to Know? a number of drawbacks that would be difficult to reconcile. These include the following. First, the duration of serological Studies that are needed to inform recommendations for perimmunity following immunization with acellular pertussis vactussis immunization among other adult groups include agecine is very short relative to immunity to tetanus or diphtheria specific morbidity data and vaccine efficacy studies with costand would probably require boosters more often than the 10-benefit analyses; safety studies in pregnant women, together year interval for tetanus-diphtheria toxoids recommended by with an evaluation of maternal antibody protection of infants most advisory groups. Second, toxicity issues of tetanusin the first months of life; evaluation of the importance of adult diphtheria toxoids vaccine related to ''over-immunization'' inimmunization in creating herd immunity; and evaluation of the clude more severe local reactions and rare neurological complirole of certain subgroups, such as health care workers, day care cations (Guillain-Barré syndrome and brachial plexus neuritis) staff, and teachers, in the epidemiology of pertussis. [16] . In addition, the recommendation for decennial boosters of tetanus-diphtheria toxoids vaccine has had low compliance and is not well supported by epidemiological data [17] . CostSummary benefit studies suggest that a single midlife booster with tetanus-diphtheria toxoids is preferable, and several advisory
The availability of acellular pertussis vaccines, which appear to be both safe and immunogenic in adults, will require that groups (American College of Physicians and the American Academy of Family Practice) have recommended this as an vaccine advisory groups make recommendations regarding their use. Pertussis in adults has negligible mortality but is alternative. If a single midlife booster becomes the standard, the need for frequent boosters with acellular pertussis vaccine responsible for about one-quarter of cases of chronic cough syndrome in young adults. Parents and other infant caregivers will not be served by combining it with tetanus-diphtheria toxoids vaccine. Finally, it is estimated that about one-half of are important transmitters of pertussis to infants, the group who have the highest morbidity and mortality. the use of tetanus-diphtheria toxoids vaccine is in the management of tetanus-prone wounds rather than as a result of the Assuming that further studies confirm the immunogenicity and safety profile of acellular pertussis vaccine in adults, recroutine booster recommendation. The addition of diphtheria toxoid to tetanus toxoid was made at a negligible cost increommendations can be made for its use for universal immunization of adolescents with a combined acellular pertussis vaccine ment. The addition of acellular pertussis vaccine to tetanusdiphtheria toxoids is likely to result in a significant cost increase and tetanus-diphtheria toxoids preparation and for epidemic control with acellular pertussis vaccine alone. It should be and may result in mild incremental toxicity. Currently, the level of awareness and concern about adult pertussis is low, both in strongly considered for targeted adults who give care to infants (either acellular pertussis vaccine alone or in combination with the medical profession and in the populace. Acceptance of a more expensive (and possibly more reactogenic) combined tetanus-diphtheria toxoids). Factors that mitigate against including acellular pertussis vaccine in the recommended decenvaccine will require favorable cost-benefit studies, as well as a major educational effort to inform the public and the medical nial booster with tetanus-diphtheria toxoids include the short duration of the immune response to acellular pertussis vaccine; community about adult pertussis and its consequences.
increased cost and reactogenicity; further reduction in the already poor compliance with the recommendation for the decenWhat Adult Uses of Acellular Pertussis Vaccine Can Be nial tetanus-diphtheria toxoids booster; and the lack of vaccine Recommended Now? delivery systems to most young adults. Studies of pregnant women are strongly recommended, not only to evaluate the Assuming that studies confirm the immunogenicity and good safety profile of acellular pertussis vaccine in adults, current benefit of protecting the most important infant caregivers but also to evaluate maternal antibody protection of infants during data support its use in the universal immunization of adolescents, presumably with tetanus-diphtheria toxoids and acellular their most vulnerable months. Other recommendations for adult uses of acellular pertussis vaccine will await cost-benefit studpertussis vaccine (an adolescent immunization visit is becoming a standard of pediatric practice and will also focus on ies. It is unlikely that the elderly and the infirm, who are the current focus of adult immunization programs, will be im-''catch-up'' immunization against hepatitis B and varicella), and in epidemic control, presumably with an acellular pertussis portant targets for adult pertussis immunization. Therefore, the / 9c69$$ju06 05-11-99 10:06:05 cida UC: CID
